'All Options On The Table,' Says Hillebrenner On Diagnostics Reform
During a recent webinar hosted by the Alliance for a Stronger FDA, Elizabeth Hillebrenner, associate director for scientific and regulatory programs at the agency’s device center, vowed to keep fighting for diagnostic reform despite Congress failing to pass the VALID Act last year.
You may also be interested in...
US FDA officials have said multiple times that they plan to move to regulate lab-developed tests, with or without Congressional action. And this week, the agency made a formal announcement of those intentions via the Unified Agenda.
Medtech Insight spoke with Stephen Hahn, ex-FDA commissioner and CEO of Harbinger Health, who attended SXSW, about the firm’s blood-based cancer test in development.
The FDA requested a 10% increase in budget authority for FY 2024, but diagnostic reform was left out of the proposal.